Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz Pharmaceuticals Buyback Yield % Related Terms
Jazz Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAZZ vs BBIO, EXEL, IONS: Buyback Yield % Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (JAZZ) has a Buyback Yield % of 0.00 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jazz Pharmaceuticals and its competitors. Over the past decade, Jazz Pharmaceuticals' Buyback Yield % has ranged from 0.08 to 8.79. According to the industry distribution chart, Jazz Pharmaceuticals ranks #999999 out of 740 companies in the Biotechnology industry.
Is Jazz Pharmaceuticals' Buyback Yield % too high?
Jazz Pharmaceuticals' current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 8.79. Based on the distribution chart, Jazz Pharmaceuticals ranks #999999 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Buyback Yield % compare to BBIO and EXEL?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #999999 out of 740 companies for Buyback Yield %. This places Jazz Pharmaceuticals in the lower half of its industry. Historically, Jazz Pharmaceuticals' own Buyback Yield % has ranged from 0.08 to 8.79 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.63, compared to a current price of $243.47 — trading 61.6% above its estimated fair value. The current Buyback Yield % is 0.00. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Buyback Yield % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of $243.47 is trading 61.6% above its estimated GF Value™ of $150.63.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for JAZZ:
Buyback Yield %: 0.00
GF Value™: $150.63 vs. price of $243.47 (61.6% above fair value)
No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for JAZZ
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAZZ has been successfully added to your 
